|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Teicher BA: Searching for molecular
targets in sarcoma. Biochem Pharmacol. 84:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gorlick R: Current concepts on the
molecular biology of osteosarcoma. Cancer Treat Res. 152:467–478.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumar MS, Lu J, Mercer KL, Golub TR and
Jacks T: Impaired microRNA processing enhances cellular
transformation and tumorigenesis. Nat Genet. 39:673–677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang M, Lin L, Cai H, Tang J and Zhou Z:
MicroRNA-145 downregulation associates with advanced tumor
progression and poor prognosis in patients suffering osteosarcoma.
Onco Targets Ther. 6:833–838. 2013.PubMed/NCBI
|
|
8
|
Shen L, Chen XD and Zhang YH: MicroRNA-128
promotes proliferation in osteosarcoma cells by downregulating
PTEN. Tumour Biol. Oct 15–2013.(Epub ahead of print).
|
|
9
|
Wang Y, Zhao W and Fu Q: miR-335
suppresses migration and invasion by targeting ROCK1 in
osteosarcoma cells. Mol Cell Biochem. 384:105–111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kota J, Chivukula RR, O’Donnell KA, et al:
Therapeutic microRNA delivery suppresses tumorigenesis in a murine
liver cancer model. Cell. 137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ji J, Shi J, Budhu A, et al: MicroRNA
expression, survival, and response to interferon in liver cancer. N
Engl J Med. 361:1437–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ciarapica R, Russo G, Verginelli F, et al:
Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.
Cell Cycle. 8:172–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Liu XX, He JR, et al:
Pathologically decreased miR-26a antagonizes apoptosis and
facilitates carcinogenesis by targeting MTDH and EZH2 in breast
cancer. Carcinogenesis. 32:2–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cabrera R and Szabo G: Another armed
CD4+ T cell ready to battle hepatocellular carcinoma.
Hepatology. 58:1–3. 2013.
|
|
15
|
Liu B, Wu X, Liu B, et al: MiR-26a
enhances metastasis potential of lung cancer cells via AKT pathway
by targeting PTEN. Biochim Biophys Acta. 1822:1692–1704. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huse JT, Brennan C, Hambardzumyan D, et
al: The PTEN-regulating microRNA miR-26a is amplified in high-grade
glioma and facilitates gliomagenesis in vivo. Genes Dev.
23:1327–1337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Han C and Wu T: MicroRNA-26a
promotes cholangiocarcinoma growth by activating β-catenin.
Gastroenterology. 143:246–256. 2012.PubMed/NCBI
|
|
18
|
Lu J, He ML, Wang L, et al: MiR-26a
inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma
through repression of EZH2. Cancer Res. 71:225–233. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sander S, Bullinger L, Klapproth K, et al:
MYC stimulates EZH2 expression by repression of its negative
regulator miR-26a. Blood. 112:4202–4212. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luzi E, Marini F, Sala SC, Tognarini I,
Galli G and Brandi ML: Osteogenic differentiation of human adipose
tissue-derived stem cells is modulated by the miR-26a targeting of
the SMAD1 transcription factor. J Bone Miner Res. 23:287–295. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gorlick R, Anderson P, Andrulis I, et al:
Biology of childhood osteogenic sarcoma and potential targets for
therapeutic development: meeting summary. Clin Cancer Res.
9:5442–5453. 2003.PubMed/NCBI
|
|
22
|
Wittig JC, Bickels J, Priebat D, et al:
Osteosarcoma: a multidisciplinary approach to diagnosis and
treatment. Am Fam Physician. 65:1123–1132. 2002.PubMed/NCBI
|
|
23
|
Sreekumar R, Sayan BS, Mirnezami AH and
Sayan AE: MicroRNA control of invasion and metastasis pathways.
Front Genet. 2:582011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang TC, Yu D, Lee YS, et al: Widespread
microRNA repression by Myc contributes to tumorigenesis. Nat Genet.
40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dews M, Homayouni A, Yu D, et al:
Augmentation of tumor angiogenesis by a Myc-activated microRNA
cluster. Nat Genet. 38:1060–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu H, Yao Y, Smith LP and Nair V:
MicroRNA-26a-mediated regulation of interleukin-2 expression in
transformed avian lymphocyte lines. Cancer Cell Int. 10:152010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dang X, Ma A, Yang L, et al: MicroRNA-26a
regulates tumorigenic properties of EZH2 in human lung
carcinoma cells. Cancer Genet. 205:113–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sparmann A and van Lohuizen M: Polycomb
silencers control cell fate, development and cancer. Nat Rev
Cancer. 6:846–856. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kleer CG, Cao Q, Varambally S, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raaphorst FM, Meijer CJ, Fieret E, et al:
Poorly differentiated breast carcinoma is associated with increased
expression of the human polycomb group EZH2 gene. Neoplasia.
5:481–488. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu C, Hou Z, Zhan P, et al: EZH2 regulates
cancer cell migration through repressing TIMP-3 in non-small cell
lung cancer. Med Oncol. 30:7132013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wagener N, Macher-Goeppinger S, Pritsch M,
et al: Enhancer of zeste homolog 2 (EZH2) expression is an
independent prognostic factor in renal cell carcinoma. BMC Cancer.
10:5242010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Richter GH, Plehm S, Fasan A, et al: EZH2
is a mediator of EWS/FLI1 driven tumor growth and metastasis
blocking endothelial and neuro-ectodermal differentiation. Proc
Natl Acad Sci USA. 106:5324–5329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Croonquist PA and Van Ness B: The polycomb
group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene
that influences myeloma cell growth and the mutant ras phenotype.
Oncogene. 24:6269–6280. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sasaki H, Setoguchi T, Matsunoshita Y, Gao
H, Hirotsu M and Komiya S: The knock-down of overexpressed EZH2 and
BMI-1 does not prevent osteosarcoma growth. Oncol Rep. 23:677–684.
2010.PubMed/NCBI
|
